Bayer AG

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Bayer AG engages in the business of life science fields of healthcare and nutrition. It operates through the following segments: Crop Science, Pharmaceuticals, and Consumer Health. The Crop Science segment includes developing, producing, and marketing products in seeds and plant traits, crop protection, digital solutions, and customer services to promote sustainable agriculture. The Pharmaceuticals segment is involved in prescription products especially for cardiology and women’s health; specialty therapeutics in the areas of oncology, hematology, ophthalmology, and cell and gene therapy; diagnostic imaging equipment; and necessary contrast agents. The Consumer Health segment focuses on non-prescription products in the dermatology, nutritional supplements, digestive health, allergy, cough and cold, and pain and cardiovascular risk prevention categories. The company was founded by Friedrich Bayer and Johann Friedrich Westkott on August 1, 1863 and is headquartered in Leverkusen, Germany.

In 2018, Bayer acquired Monsanto and is now facing 13,400 plaintiffs claiming that Roundup caused cancer.

Bayer: A Life Sciences Company Fighting For Its Life

A judge is likely to find that the verdict against Bayer violates the US Constitution's ban on excessive punitive damages.

Don't Overreact to the $2 Billion Punitive Damages Award Against Bayer

Bayer AG in court once more over allegations that the company’s ‘Roundup’ weed killer causes cancer.

Bayer: Pessimism Is Opportunity

A U.S. judge on Wednesday appointed prominent attorney Kenneth Feinberg as mediator for court-mandated settlement talks in the federal litigation over allegations that Bayer AG's glyphosate-based Roundup weed killer caused cancer.

U.S. judge appoints Ken Feinberg mediator for Bayer Roundup settlement talks

A U.S. judge has appointed prominent attorney Kenneth Feinberg as mediator for court-mandated settlement talks in the federal litigation over allegations that Bayer AG's glyphosate-based Roundup weed killer caused cancer.

U.S. judge appoints Ken Feinberg mediator in mandated Bayer Roundup settlement talks

Bayer on Tuesday hired law firm Sidley Austin to investigate a Europe-wide data collection scheme run by its Monsanto unit, which targeted journalists, politicians and other stakeholders to influence the debate on pesticides.

Bayer hires law firm to probe Monsanto data collection

Outlandish punitive figures over the Roundup debacle that will never be paid are severely depressing the stock.

No Better Time To Buy Bayer

Bayer AG plans to argue that a $2 billion jury award and thousands of U.S. lawsuits claiming its glyphosate-based weed killer Roundup causes cancer should be tossed because a U.S. regulatory agency said the herbicide is not a public health risk.

Bayer bets on 'silver bullet' defense in Roundup litigation; experts see hurdles

Bayer AG is confident its appeals of recent court rulings that its glyphosate weed killer Roundup caused cancer will be successful, a senior executive said on Thursday, amid a steep selloff of the company's shares this week.

Bayer confident of appeals of glyphosate weed killer court defeats: executive

National Beverage

Tencent Music Entertainment Group 

See why these three stocks missed out on the broader market's rise on Tuesday.

Why National Beverage, Tencent Music, and Bayer Slumped Today

Bayer shares continued to fall on Tuesday after a California jury on Monday awarded more than $2 billion in damages to a couple who alleged that the company's glyphosate-based weed killer Roundup caused their cancers.

Factbox: More Roundup trials, appeals in store for Bayer after $2 billion verdict

Bayer shares fell by as much as 5 percent on Tuesday after a California couple were awarded more than $2 billion in the largest U.S. jury penalty over allegations its Roundup weed killer causes cancer.

Bayer nears 7-year low after $2 billion award in Roundup trial

Bayer AG on Monday was ordered by a California jury to pay $2 billion to a couple who say they were diagnosed with cancer after using the company's weedkiller Roundup.

Bayer to pay $2 billion after losing suit that claims weedkiller Roundup causes cancer

Bayer said on Monday its Monsanto unit, which is being investigated by French prosecutors for compiling files of influential people such as journalists in France, likely did the same across Europe, suggesting a potentially wider problem.

Bayer says Monsanto likely kept files on influential people across Europe

Bayer said on Sunday it was hiring an outside law firm to investigate French media complaints that Monsanto, the U.S. seed maker it took over last year, had compiled a file of influential personalities.

Bayer hires law firm to investigate Monsanto stakeholder file issue

Bayer said on Saturday it did not accept "unethical behavior" following a French investigation into a suspected file assembled by the German company's seed making unit Monsanto to influence various personalities in France.

Bayer says won't tolerate unethical behavior as France probes Monsanto file

The French prosecutor on Friday said it had opened a preliminary investigation into a suspected file assembled by Bayer's seed maker Monsanto to influence various personalities in France.

French prosecutor opens investigation over suspected Monsanto file

Bayer (BAYRY) closed at $16.36 in the latest trading session, marking a +0.46% move from the prior day.

Bayer (BAYRY) Outpaces Stock Market Gains: What You Should Know

Bayer announced that it had its NDA accepted by FDA for review of darolutamide to treat patients with non-metastatic castration-resistant prostate cancer for potential approval in the United States.

Bayer Presses Forward With Potential FDA Approval In A Market Riddled With Competitors

Bayer (BAYRY) exceeds earnings estimates in the first quarter of 2019 and sales rise year over year.

Bayer (BAYRY) Q1 Earnings Beat Estimates, Revenues Up Y/Y

Bayer (BAYRY) has been upgraded to a Zacks Rank #1 (Strong Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.

Bayer (BAYRY) Upgraded to Strong Buy: What Does It Mean for the Stock?

Bayer (BAYRY) is expected to provide pipeline updates along with its first-quarter results.

What's in Store for Bayer (BAYRY) This Earnings Season?

Bayer (BAYRY) closed at $17.02 in the latest trading session, marking a -1.33% move from the prior day.

Bayer (BAYRY) Stock Moves -1.33%: What You Should Know

Bayer (BAYRY) closed the most recent trading day at $17.28, moving -0.06% from the previous trading session.

Bayer (BAYRY) Stock Sinks As Market Gains: What You Should Know

AbbVie

AstraZeneca

Bristol-Myers

Johnson & Johnson

Eli Lilly

Novartis

AstraZeneca announces a $6.9 billion cancer deal with Daiichi Sankyo. AbbVie (ABBV), Novartis (NVS) & AstraZeneca's (AZN) drugs get regulatory approvals.

News for Bayer AG Stock (BAYRY)